{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:21:58Z","timestamp":1789543318634,"version":"build-2803163510"},"reference-count":30,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v102.1433","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T08:51:48Z","timestamp":1644569508000},"page":"adv00650","source":"Crossref","is-referenced-by-count":4,"title":["Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma"],"prefix":"10.2340","volume":"102","author":[{"given":"Tanja","family":"Batinac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Hla\u010da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Simeti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frane","family":"Valkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Peternel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Prpi\u0107-Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"15407","doi-asserted-by":"crossref","unstructured":"Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, et al. Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 2019; 4: e000491.","DOI":"10.1136\/esmoopen-2019-000491"},{"key":"15408","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000491","DOI":"10.1136\/esmoopen-2019-000491"},{"key":"15409","doi-asserted-by":"crossref","unstructured":"O'Reilly A, Larkin J. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. Expert Rev Anticancer Ther 2017; 17: 647-655.","DOI":"10.1080\/14737140.2017.1341315"},{"key":"15410","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14737140.2017.1341315","DOI":"10.1080\/14737140.2017.1341315"},{"key":"15411","doi-asserted-by":"crossref","unstructured":"Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R. Systematic review of BRAF\/MEK inhibitors-induced severe cutaneous adverse reactions (SCARs). J Eur Acad Dermatol Venereol 2021; 35: 607-614.","DOI":"10.1111\/jdv.16894"},{"key":"15412","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16894","DOI":"10.1111\/jdv.16894"},{"key":"15413","doi-asserted-by":"crossref","unstructured":"Dr\u00e9no B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 2017; 28: 1137-1144.","DOI":"10.1093\/annonc\/mdx040"},{"key":"15414","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdx040","DOI":"10.1093\/annonc\/mdx040"},{"key":"15415","doi-asserted-by":"crossref","unstructured":"Lamiaux M, Scalbert C, Lepesant P, Desmedt E, Templier C, Dziwniel V, et al. Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. Melanoma Res 2018; 28: 451-457.","DOI":"10.1097\/CMR.0000000000000472"},{"key":"15416","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/CMR.0000000000000472","DOI":"10.1097\/CMR.0000000000000472"},{"key":"15417","doi-asserted-by":"crossref","unstructured":"Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, et al. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer 2019; 125: 884-891.","DOI":"10.1002\/cncr.31889"},{"key":"15418","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.31889","DOI":"10.1002\/cncr.31889"},{"key":"15419","doi-asserted-by":"crossref","unstructured":"Gey A, Milpied B, Dutriaux C, Mateus C, Robert C, Perro G, et al. Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? J Eur Acad Dermatol Venereol 2016; 30: 178-179.","DOI":"10.1111\/jdv.12685"},{"key":"15420","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12685","DOI":"10.1111\/jdv.12685"},{"key":"15421","doi-asserted-by":"crossref","unstructured":"Tahseen AI, Patel NB. Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma. JAAD Case Rep 2018; 4: 930-933.","DOI":"10.1016\/j.jdcr.2018.08.003"},{"key":"15422","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdcr.2018.08.003","DOI":"10.1016\/j.jdcr.2018.08.003"},{"key":"15423","doi-asserted-by":"crossref","unstructured":"Pinard C, Mignard C, Samain A, Duval-Modeste A-B, Joly P. Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib. JAAD Case Rep 2017; 3: 532-533.","DOI":"10.1016\/j.jdcr.2017.06.027"},{"key":"15424","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdcr.2017.06.027","DOI":"10.1016\/j.jdcr.2017.06.027"},{"key":"15425","doi-asserted-by":"crossref","unstructured":"Broman KK, Dossett LA, Sun J, Eroglu Z, Zager JS. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opin Drug Saf 2019; 18: 381-392.","DOI":"10.1080\/14740338.2019.1607289"},{"key":"15426","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14740338.2019.1607289","DOI":"10.1080\/14740338.2019.1607289"},{"key":"15427","doi-asserted-by":"crossref","unstructured":"Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB, et al. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF\/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer 2019; 7: 4.","DOI":"10.1186\/s40425-018-0475-y"},{"key":"15428","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s40425-018-0475-y","DOI":"10.1186\/s40425-018-0475-y"},{"key":"15429","doi-asserted-by":"crossref","unstructured":"Poduje S, Brozi\u0107 JM, Prka\u010din I, Dela\u0161 A\u017edaji\u0107 M, Goren A. Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma. Dermatol Ther 2020; 33: e13174.","DOI":"10.1111\/dth.13174"},{"key":"15430","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13174","DOI":"10.1111\/dth.13174"},{"key":"15431","doi-asserted-by":"crossref","unstructured":"Maximova N, Maestro A, Zanon D, Marcuzzi A. Rapid recovery of post nivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration. J Immunother Cancer 2020; 8: e000388.","DOI":"10.1136\/jitc-2019-000388"},{"key":"15432","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/jitc-2019-000388","DOI":"10.1136\/jitc-2019-000388"},{"key":"15433","doi-asserted-by":"crossref","unstructured":"Loyson T, Werbrouck E, Punie K, Bonne L, Vandecaveye V, Bechter O. Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF\/MEK inhibition in metastatic melanoma: a case report. Melanoma Res 2018; 28: 147-150.","DOI":"10.1097\/CMR.0000000000000419"},{"key":"15434","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/CMR.0000000000000419","DOI":"10.1097\/CMR.0000000000000419"},{"key":"15435","doi-asserted-by":"crossref","unstructured":"Sato R, Imamura K, Sakata S, Ikeda T, Horio Y, Iyama S, et al. Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies. J Clin Med 2019; 8: 762.","DOI":"10.3390\/jcm8060762"},{"key":"15436","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm8060762","DOI":"10.3390\/jcm8060762"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1433\/2825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1433\/2826","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1433\/2825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T17:18:17Z","timestamp":1655918297000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/1433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.1433","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}